2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Jason R. Westin, MD, discusses the 2-year follow-up data of the ongoing phase 1 TRANSCEND-NHL-001 trial in relapsed/refractory large B-cell lymphoma.
Jason R. Westin, MD, director, Lymphoma Clinical Research, section chief, Aggressive Lymphoma, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the 2-year follow-up data of the ongoing phase 1 TRANSCEND-NHL-001 (NCT02631044) trial in relapsed/refractory large B-cell lymphoma (LBCL).
The long-term update for the trial was beneficial, as it further supported that lisocabtagene maraleucel (liso-cel; Breyanzi) is an active and effective therapy with a favorable toxicity profile in this patient population, Westin says. Earlier data from the trial showed durable responses with liso-cel; the long-term data showed that these responses were maintained in a significant proportion of patients. The median duration of response was 23.1 months and the probability rate of continued response at 2 years was 49.5%, Westin explains. Moreover, the rates of probability of 2-year progression-free survival and overall survival were 40.6% and 50.5%, respectively.
Based upon these data, as well as follow-up data from other trials examining CAR T-cell therapies, such as ZUMA-1 (NCT02348216) and JULIET (NCT02445248), a proportion of patients appear to be cured with these therapies when they are used in the third-line setting, Westin concludes.